Literature DB >> 8674161

Biological characterization of L-asparaginase liposomal formulations.

M M Gaspar1, R Perez-Soler, M E Cruz.   

Abstract

The biological properties of preselected liposomal formulations of L-asparaginase (L-ASNase) were studied. Pharmacokinetics studies showed that encapsulation in large liposomes (sDRV; median diameter 1,249 nm) decreased the circulation time of the enzyme, whereas encapsulation in small liposomes (VET: median diameter 158-180 nm) prolonged it by a factor of up to 10. Liposome encapsulation in either VET or sDRV prevents the induction of anti-asparaginase antibodies and mitigates the anaphylatic reaction, as no death occurred in animals presensitized and challenged with liposomal formulation, in contrast to animals treated with the free enzyme. The antitumor activity was also enhanced by liposome encapsulation. The survival of animals bearing P1534 tumors was prolonged by a factor of 2 after treatment with selected liposomal formulations as compared with free enzyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674161     DOI: 10.1007/s002800050497

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection.

Authors:  M M Gaspar; S Neves; F Portaels; J Pedrosa; M T Silva; M E Cruz
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  NANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.

Authors:  John N Barry; Alexey A Vertegel
Journal:  Nano Life       Date:  2013-12-27

3.  Effect of premedications in a murine model of asparaginase hypersensitivity.

Authors:  Christian A Fernandez; Colton Smith; Seth E Karol; Laura B Ramsey; Chengcheng Liu; Ching-Hon Pui; Sima Jeha; William E Evans; Fred D Finkelman; Mary V Relling
Journal:  J Pharmacol Exp Ther       Date:  2015-01-08       Impact factor: 4.030

4.  In vivo half life of nanoencapsulated L-asparaginase.

Authors:  E T Baran; N Ozer; V Hasirci
Journal:  J Mater Sci Mater Med       Date:  2002-12       Impact factor: 3.896

Review 5.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging.

Authors:  Vladimir P Torchilin
Journal:  AAPS J       Date:  2007-05-11       Impact factor: 4.009

Review 6.  Delivery of therapeutic proteins.

Authors:  Dipak S Pisal; Matthew P Kosloski; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

7.  Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL.

Authors:  Rekha Raghunathan; Swetha Mahesula; Kranthi Kancharla; Preethi Janardhanan; Yeshwant L A Jadhav; Robert Nadeau; German P Villa; Robert L Cook; Colleen M Witt; Jonathan A L Gelfond; Thomas G Forsthuber; William E Haskins
Journal:  Part Part Syst Charact       Date:  2013-04       Impact factor: 3.310

8.  Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment.

Authors:  Cristina Díaz-Barriga; Francisca Villanueva-Flores; Katrin Quester; Andrés Zárate-Romero; Ruben Dario Cadena-Nava; Alejandro Huerta-Saquero
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

9.  Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study.

Authors:  Elham Bahreini; Khosrow Aghaiypour; Roghayeh Abbasalipourkabir; Ali Rezaei Mokarram; Mohammad Taghi Goodarzi; Massoud Saidijam
Journal:  Nanoscale Res Lett       Date:  2014-07-09       Impact factor: 4.703

Review 10.  Next generation delivery system for proteins and genes of therapeutic purpose: why and how?

Authors:  Ashish Ranjan Sharma; Shyamal Kumar Kundu; Ju-Suk Nam; Garima Sharma; C George Priya Doss; Sang-Soo Lee; Chiranjib Chakraborty
Journal:  Biomed Res Int       Date:  2014-07-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.